Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00950352 · ClinicalTrials.gov registry record · Phase 3
Citicoline Treatment of Methamphetamine Dependence
A Phase 3 study, sponsored by Perry Renshaw.
- Completed
- Registry status
- Phase 3
- Development phase
- 104
- Enrollment target
NCT00950352: Completed Phase 3 study, sponsored by Perry Renshaw.
NCT00950352 is a Phase 3 study that has completed, run by Perry Renshaw. The registered enrollment target is 104 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00950352, a Phase 3 study, has completed, sponsored by Perry Renshaw.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 104 participants
- Enrollment target
Study Summary
The purpose of the study is to determine if citicoline (a nutritional supplement) is effective in helping people reduce their dependence on methamphetamine. The investigators will use neuroimaging to look at the structure and chemical make up of the brain at the start of the study and after 8-9 weeks of treatment of citicoline or placebo.
Primary Outcome
Total Amount of Methamphetamine consumed by the participants after 8-9 weeks of treatment. Methamphetamine was assessed twice weekly.
Interventions
- DRUG Placebo
- DRUG Citicoline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2010-01 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
What the finished NCT00950352 record still lists
NCT00950352 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00950352 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00950352 about?
NCT00950352 is a clinical study titled "Citicoline Treatment of Methamphetamine Dependence". The purpose of the study is to determine if citicoline (a nutritional supplement) is effective in helping people reduce their dependence on methamphetamine. The investigators will use neuroimaging to look at the structure and chemical make up of the brain at the start of the study and after 8-9 week...
What is the current status of trial NCT00950352?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 104 participants. The study started on 2010-01. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00950352?
The interventions under investigation include: Placebo (DRUG), Citicoline (DRUG).
Who is sponsoring clinical trial NCT00950352?
This trial is sponsored by Perry Renshaw, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00950352's enrollment target sits among peer trials
104 1671st of 2000 higher than 327 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia